Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. - Peeters, M (J Clin Oncol, 2010)
DOI:10.1200/JCO.2009.27.6055.